Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: Effect of enalapril

Cardiovascular Drugs and Therapy

Volumn 11, Issue 2, 1997, Pages 177-185

  Pelouch, V ^a   Kolar F ^a   Ost'adal B ^a   Milerova M ^a   Cihak R ^b   Widimsky J ^b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b Department of Neurology   (Czech Republic)

Author keywords

Chronic hypoxia; Collagen; Enalapril; Fibrosis; Pulmonary hypertension; Right ventricular hypertrophy

Indexed keywords

COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ALTITUDE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART RATE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPOXIA; LUNG ARTERY PRESSURE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

ALTITUDE SICKNESS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANOXIA; BODY WEIGHT; CHRONIC DISEASE; COLLAGEN; ENALAPRIL; HEMODYNAMIC PROCESSES; HYDROXYPROLINE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MYOCARDIUM; ORGAN SIZE; PULMONARY FIBROSIS; RATS; RATS, WISTAR;

EID: 0030904985     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007788915732     Document Type: Article

References (52)

1. Durand J. Physiologic adaptation to altitude and hyperexis. In: Brendel W, Zink RA, eds. High Altitude Physiology and Medicine. New York: Springer-Verlag, 1982:209-211.
2. Widimský J, Urbanová D, Ressl J, Ošt'ádal B, Pelouch V, Procházka J. Effect of intermittent altitude hypoxia on the myocardium and lesser circulation in the rat. Cardiovasc Res 1973;7:798-808.
3. Herget J, Paleček F. Experimental chronic pulmonary hypertension. Int Rev Pathol 1978;18:347-406.
4. Ošt'ádal B, Kolář F, Pelouch V, Procházka J, Widimský J. Intermittent high altitude and the cardiopulmonary system. In: Nagano M, Takeda N, Dhalla NS, eds. Adapted Heart. New York: Raven Press, 1994:173-182.
5. Reid LM. Structure and function in pulmonary hypertension. New perceptions. Chest 1986;89:279-288.
6. Pelouch V, Ošt'ádal B, Procházka J, Urbanová D, Widimský J. Effect of high altitude hypoxia on the protein composition on the right ventricular myocardium. Progr Resp Res 1985;20:41-48.
7. Pelouch V, Dixon IMC, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem 1994;129:101-120.
8. Ressl J, Urbanová D, Widimský J, Ošt'ádal B, Pelouch V, Procházka J. Reversibility of pulmonary hypertension and right ventricular hypertrophy induced by intermittent high altitude hypoxia in rats. Respiration 1974;31:38-46.
9. Ošt'ádal B, Procházka J, Pelouch V, Urbanová D, Widimský J, Staněk V. Pharmacological treatment and spontaneous reversibility of cardiopulmonary changes induced by intermittent high altitude hypoxia. Prog Respir Res 1985;29:17-25.
10. Weber KT, Brilla CG, Janicki JS. Signals for the remodeling of the cardiac interstitium in systemic hypertension. J Cardiovasc Pharmacol 1991;17:514-519.
11. Weber KT, Janicki JS. Angiotensin and the remodeling of the myocardium. Br J Clin Pharmacol 1989;28:141S-150S.
12. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990;67:1355-1364.
13. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-1779.
14. Baker KM, Boos GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992;54:227-241.
15. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: A one year study in rats. Br J Pharmacol 1992;107:970-975.
16. Linz W, Gohlke P, Unger T, Schölkens BA. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur Vaiss 1995;88:31-34.
17. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley KH. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat. Lab Invest 1975;33:57-61.
18. Suggett AJ, Mohammed FH, Barer GR. Anginotensin, hypoxia, verapamil and pulmonary vessels. Clin Exp Pharmacol Physiol 1980;7:263-274.
19. Kentera D, Susie D, Cvetkovic D, Djorjevic G. Effect of SQ 14 225, an orally active inhibitor of angiotensin converting enzyme, on hypoxic pulmonary hypertension in rats. Basic Res Cardiol 1981;76:344-351.
20. Clozel JP, Saunier C, Harteman D, Fischli W. Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries of rats exposed to chronic hypoxia. J Cardiovasc Pharmacol 1991;17:36-40.
21. Kay JM, Keane PM, Suyama KL, Gauthier D. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax 1982;37:88-96.
22. Molteni A, Ward WF, Tsao CH, Solliday NH. Monocrotaline-induced cardiopulmonary damage in rats: Amelioration by the angiotensin-converting enzyme inhibitor C 1242817 (24370). Proc Soc Exp Biol Med 1986;182:483-493.
23. Cassis LA, Rippetoe PE, Soltis EE, Painter DJ, Fitz R, Gillespie MN. Angiotensin II and monocrotaline-induced pulmonary hypertension: Effect of Losartan (DuP 753) a nonpeptide angiotensin type 1 receptor antagonist. J Pharmacol Exp Ther 1992;262:1168-1172.
24. Tanaka K., Honda M, Kuramochi T, et al. Different effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on protein metabolism in rats with right ventricular hypertrophy. J Hypertens 1994;12:1147-1154.
25. Ishikawa K, Hashimoto H, Mitani S, Toki Y, Okumura K, Ito T. Enalapril improves heart failure induced by monocrotaline without reducing pulmonary hypertension in rats: Roles of preserved myocardial creatine kinase and lactate dehydrogenase isoenzymes. Int J Cardiol 1995;47:225-233.
26. Abraham WT, Raynolds MV, Gottschall B, et al. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 1995;86:9-15.
27. Zierhut W, Zimmer HG, Gerdes AM. Influence of ramipril on ventricular hypertrophy induced by pulmonary artery stenosis in rats. J Cardiovasc Pharmacol 1990;16:480-486.
28. Zimmer HG. Development and modulation of experimental right ventricular hypertrophy in rats. J Cardiovasc Pharmacol 1992;20:S1-S6.
29. Pelouch V, Milerová M, Ošt'ádal B, Hučin B, Šamánek M. Differences between atrial and ventricular protein profiling in children with congenital heart disease. Mol Cell Biochem 1995;147:43-49.
30. Pelouch V, Dixon IMC, Sethi R, Dhalla NS. Alteration of collagenous profile in congestive heart failure secondary to myocardial infarction. Mol Cell Biochem 1994b-9:121-131.
31. Brilla CG, Maisch B, Rupp H, Funck R, Zhou B, Weber KT. Pharmacological modulation of cardiac fibroblast function. Herz 1995;20:127-134.
32. Zimmer HG, Gerdes AM, Lortet S, Mall G. Changes in heart function and cardiac cell size in rats with chronic myocardial infarction. J Mol Cell Cardiol 1990;22:1231-1243.
33. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1994;27:341-348.
34. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors: The experimental evidence. Cardiovasc Res 1994;28:183-189.
35. Nishimiki T, Yamagishi H, Takeuchi T, Takeda T. An angiotenisn II receptor antagonist attenuated left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29:856-861.
36. Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential. Cardiovasc Res 1994;28:146-158.
37. 1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats Cardiovasc Res 1994;31:568-576.
38. Studer R, Reinecke H, Müller B, Holtz J, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994;94:301-310.
39. Rodman DM, Voelkel NF. Regulation of vascular tone. In: Crystal RG, ed. The Lung. New York: Raven Press, 1991:1105-1119.
40. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-877.
41. Herget J, Pelouch V, Kolář F, Oŝt'àdal B. The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat. Physiol Res 1996;45:221-226.
42. Rabinovitch M, Gamble WJ, Williams G, Reid L. SQ 14,225 converting enzyme inhibitor diminishes pulmonary artery hypertension secondary to chronic hypoxia in the rat. Fed Proc 1980;39:765.
43. Iimoto DS, Covell JW, Harper E. Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ Res 1988;63:399-408.
44. Eghbali M, Weber KT. Collagen and the myocardium: Fibrillar structure, biosynthesis, and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 1990; 96:1-14.
45. Mukherjee D, Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: Role of blood pressure. J Mol Cell Cardiol 1993;5:185-196.
46. Pelouch V, Jirmář R. Biochemical characteristics of cardiac collagen and its role in ventricular remodelling following infarction. Physiol Res 1993;42:283-292.
47. Tyagi SC, Kumar SG, Haas SJ, et al. Posttranscriptional regulation of extracellular matrix metalloproteinase in human end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996;28:1415-1428.
48. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
49. Bruckschlegel G, Holmer SR, Jandeleit K, et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 1995;25:250-259.
50. Jouquey S, Stepniewski JP, Hamon G. Trandolapril dose-response in spontaneously hypertensive rats: Effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol 1994;23:S16-S18.
51. Keeley FW, Elmoselhi A, Leenen FHH. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol 1992;262:H1013-H1021.
52. ACC/AHA Task Force Heart Failure Guidelines. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol 1995;26:1376-1398.